Brookline Capital Acquisition Issues Positive Forecast for C4 Therapeutics (NASDAQ:CCCC) Stock Price

C4 Therapeutics (NASDAQ:CCCC) had its target price hoisted by analysts at Brookline Capital Acquisition from $20.00 to $30.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other research firms also recently issued reports on CCCC. TD Cowen assumed coverage on C4 Therapeutics in a research note on Tuesday, December 2nd. They issued a “buy” rating on the stock. Barclays cut their target price on shares of C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.80.

C4 Therapeutics Price Performance

Shares of CCCC stock traded up $0.06 during trading hours on Monday, hitting $2.22. The stock had a trading volume of 999,602 shares, compared to its average volume of 1,326,316. The stock has a market capitalization of $214.66 million, a price-to-earnings ratio of -1.32 and a beta of 2.96. C4 Therapeutics has a one year low of $1.09 and a one year high of $3.65. The stock’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $2.35.

Institutional Trading of C4 Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CCCC. Engineers Gate Manager LP boosted its stake in C4 Therapeutics by 49.9% during the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock worth $47,000 after buying an additional 8,130 shares during the period. Man Group plc raised its stake in shares of C4 Therapeutics by 15.0% in the third quarter. Man Group plc now owns 90,278 shares of the company’s stock valued at $200,000 after acquiring an additional 11,791 shares during the period. Zacks Investment Management bought a new stake in shares of C4 Therapeutics in the 3rd quarter worth about $29,000. Invesco Ltd. boosted its stake in shares of C4 Therapeutics by 11.1% during the 2nd quarter. Invesco Ltd. now owns 155,017 shares of the company’s stock worth $222,000 after purchasing an additional 15,531 shares during the period. Finally, Bank of America Corp DE grew its holdings in C4 Therapeutics by 0.9% during the 2nd quarter. Bank of America Corp DE now owns 2,008,004 shares of the company’s stock valued at $2,871,000 after purchasing an additional 17,180 shares during the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.